NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain–(BUSINESS WIRE)– #HD–Prilenia Therapeutics B.V. and Ferreri today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington’s disease (HD) has received authorization to begin in participating EU Member States (clinicaltrialsregister.eu 2026-526093-16-00, clinicaltrials.gov NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, wi